Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 1:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,203 matching trials from the live ClinicalTrials.gov search.
Conditions
Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
oxaliplatin, capecitabine, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Conditions
BRCA1 Mutation, Breast Cancer
Interventions
recombinant human chorionic gonadotropin, microarray analysis, immunohistochemistry staining method, laboratory biomarker analysis, needle biopsy
Biological · Genetic · Other + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Interventions
Cisplatin, Computed Tomography, Gastrectomy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Paclitaxel, Hyperthermic Intraperitoneal Chemotherapy
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
Carboplatin, Paclitaxel, Gene expression profiling (analysis) of tumor samples
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
Procedure · Biological · Device + 3 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
285
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more
Conditions
Colorectal Cancer
Interventions
mutation analysis, tumor replication error analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
44
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 27 more
Conditions
Pancreatic Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
3
States / cities
Nashville, Tennessee
Conditions
Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Fianlimab, Magnetic Resonance Imaging, Surgical Procedure, Computed Tomography, Positron Emission Tomography
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Gastric Cancer, Gastric Neoplasm, Gastrointestinal Stromal Sarcoma, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor (GIST)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
6 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Lexington, Kentucky + 2 more
Conditions
Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Conventional Surgery, Questionnaire Administration, Stereotactic Radiosurgery, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
4
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Bethesda, Maryland + 1 more
Conditions
Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Triapine
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
recombinant fowlpox-TRICOM vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Bone Sarcoma, Osteosarcoma, Chondrosarcoma, Ewing's Sarcoma, Osseous Sarcoma, Bone Neoplasm
Interventions
Toronto Extremity Salvage Score, Musculoskeletal Tumor Society Score, Timed Get Up and Go Test, Orthogonal Radiographs, Weight Bearing for lower extremities only, Range of Motion
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
4 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 2 more
Conditions
Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Hepatocellular Carcinoma
Interventions
propranolol hydrochloride, Correlative Studies
Drug · Other
Lead sponsor
William Carson
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Medullary Thyroid Cancer, Colon Cancer
Interventions
Tumor Genomic Analysis
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Colorectal Cancer
Interventions
All eligible subjects will provide blood for SEPT9 biomarker testing
Other
Lead sponsor
Epigenomics, Inc
Industry
Eligibility
50 Years and older
Enrollment
7,929 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
20
States / cities
Boca Raton, Florida • Miami, Florida • Atlanta, Georgia + 15 more
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, EGFRt/19-28z/IL-12 CAR T-lymphocytes, Fludarabine Phosphate, Leukapheresis, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET Scan, Sipuleucel-T
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California